COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Food and Drug Administration last week issued an emergency use authorization for Cue Health Inc.’s new SARS-CoV-2 nasal swab test in patient care settings.
The Centers for Disease Control and Prevention has consolidated its recommendations for COVID-19 testing, which it will update as additional information becomes available.
The Food and Drug Administration said it no longer authorizes the use of hydroxychloroquine or chloroquine as an effective treatment of COVID-19.
The Centers for Disease Control and Prevention released guidance on using telehealth to expand access to health care services during the COVID-19 pandemic and beyond.
The Food and Drug Administration authorized the first COVID-19 diagnostic test with next generation sequencing, which can generate information about the genomic sequence of the SARS-CoV-2 coronavirus.
About 60% of participants in a study of young adults infected with COVID-19 on a U.S. aircraft carrier had reactive antibodies to the virus, 59% of whom also had neutralizing antibodies at the time of specimen collection, according to a report released by the Centers for Disease Control and…
AHA submitted comment to the Centers for Medicare & Medicaid Services on the agency’s proposed skilled nursing facility prospective payment system for fiscal year 2021, urging CMS to support additional funds to offset the cost of critically important COVID-19 testing.
The Food and Drug Administration does not intend to object to a manufacturer or authorized distributor delivering prescription drug samples directly to licensed practitioners or their patients at their homes during the COVID-19 emergency when requested by the practitioner in accordance with…
The Centers for Medicare & Medicaid Services released a guide for patients considering in-person, non-emergency treatment as the country continues to reopen and COVID-19 cases decline.
FDA released new guidance that expands for the duration of the COVID-19 emergency the availability and capability of non-invasive monitoring devices.